Mylan inc. is a multi-national pharmaceutical company producing both generic and specialised drugs. The corporation is involved in the production of various pharmaceutical ingredients and medicines for the treatment of the respiratory tract, allergies and psychological disorders. The company product line boasts over 2,700 different names. The company was founded in 1961 in West Virginia. Geographical revenue diversification (share): USA: 51.4%, other countries from North and South America: 2.7%, Europe: 23.4%, other countries: 22.5%.
It is expected that the takeover of competitor Meda Aktiebolag in 2016 will result in revenue growth, increased efficiency and higher profitability for Mylan, a bolstered range of products and faster expansion in emerging markets such as China, Southeast Asia, the Middle-East and Russia. For the moment, Mylan is continuing to show improved financial results. In the second quarter of 2016, revenue rose by 16.86% (QoQ), and by 19.39% (QoQ) in the third (the ratio of net profit to revenue in the third quarter amounted to 10.8%). The company debt load continues to fall; the ratio of debt to total assets in the third quarter of 2016 fell to 43.29% from 46.76% in the second quarter.
Investment period ends: 21/07/2017
Expected yield is calculated according to 96% capital protection and the price of the base asset at expiry, equal to 59 USD.
Mylan share price has broken upwards through the 50- and 100- daily moving averages and left the Ichimoku indicator cloud upwards. An upward trend is starting to form. The significant technical levels are: 16.65; 19.02; 20.88; 22.50; 24.00; 25.62; 27.86; 29.85; 31.60; 34.00; 35.99; 37.97; 39.95; 41.93; 43.68; 46.44; 49.41; 52.82; 55.35; 58.32; 62.39; 65.36; 68.00; 71.74; 75.04.